<DOC>
	<DOCNO>NCT00370214</DOCNO>
	<brief_summary>The REVEAL Registry™ multicenter , observational , U.S.-based study clinical course disease management pulmonary arterial hypertension ( PAH ) patient . All consecutive consenting patient diagnose WHO Group I PAH accord specific hemodynamic criterion participate institution enrol . Participating patient follow minimum five year time enrollment .</brief_summary>
	<brief_title>REVEAL Registry™ : Registry Evaluate Early And Long-term PAH Disease Management</brief_title>
	<detailed_description>Pulmonary arterial hypertension ( PAH ) chronic , progressive , often fatal disease characterize severe constriction blood vessel lung . Over past decade , significant stride make medical management understanding PAH . However , much remains learn clinical course idiopathic PAH associate PAH , include clinical presentation , pace progression , key parameter monitor , impact treatment , prognosticator outcome . As unique body knowledge generate REVEAL Registry grow , hop new understanding , insight , treatment emerge improve life patient PAH . The REVEAL Registry provide investigator descriptive data regard clinical course treatment outcomes patient WHO Group I PAH . Data derive study may offer important tool assess current management practice treat investigator , well change time . Additionally , relationship patient- disease-specific parameter patient outcome may able assessed analysis data study . The specific objective REVEAL Registry™ : - Characterize demographic clinical course PAH patient - Evaluate compare patient outcomes - Identify clinical predictor short-term long-term clinical outcome - Assess relationship PAH medication patient outcomes - Report temporal trend treatment outcomes newly diagnose patient - Collect timely relevant data evolve research need PAH community</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<criteria>Newly diagnose previously diagnose patient WHO Group I PAH . Documentation follow hemodynamic parameter right heart catheterization , perform time prior study enrollment : Mean pulmonary arterial pressure ( mPAP ) &gt; 25 mm Hg rest mPAP &gt; 30 mm Hg exercise contemporaneous pulmonary wedge pressure ≤ 18 mm Hg Pulmonary wedge pressure ≤ 18 mm Hg Pulmonary vascular resistance ( PVR ) ≥ 240 dynes.sec.cm5 ( i.e. , ≥ 3.0 Wood unit ) Patients meet criterion inclusion WHO Groups II , III , IV V Have documentation hemodynamic criterion PAH right heart catheterization time precede study entry follow development symptom associate PAH . Do meet require hemodynamic criterion entry study</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Pulmonary arterial hypertension</keyword>
	<keyword>Lung disease</keyword>
	<keyword>Heart disease</keyword>
	<keyword>Pulmonary circulation</keyword>
	<keyword>Vascular resistance</keyword>
	<keyword>PAH</keyword>
	<keyword>Hypertension</keyword>
</DOC>